Lexicon Pharmaceuticals, Inc. LXRX R3KPHARMA

Q: What is the current share price of Lexicon Pharmaceuticals, Inc. (LXRX)?

As of 2026-09-19 21:16 PDT, Lexicon Pharmaceuticals, Inc. (LXRX) trades at $2.23 on NasdaqCM. Its 52-week range is $1.07 to $2.64.

Q: What is the market capitalisation of LXRX?

Lexicon Pharmaceuticals, Inc. (LXRX) has a market capitalisation of $992.25M on NasdaqCM.

Q: What is the P/E ratio of LXRX?

LXRX trades at a trailing price-to-earnings (P/E) ratio of -13.94. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.23.

Q: What is the return on equity (ROE) of LXRX?

LXRX has a return on equity (ROE) of -40.21%. Its return on capital employed (ROCE) is -29.80%.

Q: Is LXRX a good stock to buy?

This page provides a data-driven analysis of Lexicon Pharmaceuticals, Inc. (LXRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.lexpharma.com

Company Profile ↓

$2.23

+100.90% 1Y

Mkt Cap$992.25M

P/E-13.94

P/B5.23

52W High$2.64

52W Low$1.07

Book Value$0.39

EPS (TTM)$-0.16

Company Overview

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 10.8% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.34.

Recent Developments

Dec 2025 Revenue of $49.80M (+60.2% YoY); net profit $-50.34M.
Trailing 12 Months Year-on-year growth — revenue -97.6%.
5-Year Trend Long-term compounding — revenue CAGR 10.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	10.80%
1 Year:	-97.60%

Stock Price Performance

1 Year:	+100.90%
6 Months:	+32.74%
3 Months:	+18.62%
1 Month:	-9.72%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 74% of range

$1.07 $2.64

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMAAbove
RSI (14)44.98 · Neutral

Price Performance

1M-9.72%

3M+18.62%

6M+32.74%

1Y+100.90%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 10.8% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-13.94

Industry PE

24.83

Forward P/E

-11.70

PEG Ratio

-13.77

Book Value

$0.39

Price to Book

5.23

P/S

22.00

EV/EBITDA

-14.33

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

10.80%

Profit 5Y

Revenue (YoY)

-97.60%

Earnings (YoY)

Profitability & Returns

ROCE

-29.80%

ROE

-40.21%

ROA

-14.32%

Profit Margin

Op Margin

Gross Margin

86.02%

EPS (Latest Qtr)

$-0.07

EPS (TTM)

$-0.16

Balance Sheet & Liquidity

Debt/Equity

0.34

Quick Ratio

13.07

Current Ratio

13.37

Debt

$59.24M

Total Assets

$250.06M

Current Assets

$101.89M

Working Capital

$81.03M

Ownership

Promoter Holding

1.12%

Chg in Prom Hold

-0.00%

FII / Inst Holding

83.75%

Chg in FII Hold

0.06%

Financial Snapshot

Enterprise Value

$992.25M

Total Revenue (TTM)

$41.47M

EBITDA

$-54.02M

Free Cash Flow

$-44.77M

Operating Cash Flow

$-64.99M

Shares Outstanding

444.96M

Gross Margin

86.02%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	LXRX Lexicon Pharmaceuticals, Inc. R3KPHARMA	2.23	-13.94	$992.25M	0.00%	-29.80%	-40.21%	10.80%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	19.83M	6.40M	556.00K	-	2.44M	860.00K	285.91M	-	8.00K	25.00K	0	0	0	0	-	0	0	0	291.00K	148.00K	1.09M	1.62M	1.74M	1.26M	-	-	-	-
Operating Income	-26.53M	-26.69M	-33.68M	88.36M	-33.87M	-37.02M	-34.93M	-31.33M	-39.51M	-33.49M	-28.61M	-29.02M	-37.71M	-30.27M	-22.93M	-12.37M	-17.47M	-18.55M	224.68M	-47.22M	-62.44M	-64.58M	86.67M	-20.84M	-17.96M	-22.96M	-23.38M	-24.01M	-23.09M	-31.14M	-44.24M	-49.63M	-45.33M	-55.35M	-63.69M	-25.68M	3.74M	-12.19M	-996.00K	-26.54M
Net Income	-28.08M	-28.07M	-35.28M	-	-34.88M	-38.11M	-36.02M	-32.42M	-31.92M	-34.66M	-29.81M	-26.61M	-41.82M	-34.55M	-27.40M	-16.78M	-21.80M	-23.02M	226.09M	-51.14M	-66.61M	-69.07M	82.60M	-20.96M	-18.07M	-23.12M	-23.48M	-24.59M	-23.39M	-31.93M	-44.90M	-50.52M	-48.40M	-53.43M	-64.81M	-25.30M	3.25M	-12.77M	-1.04M	-31.77M
Diluted EPS	-0.27	-0.27	-0.34	0.76	-	-	-	-	-	-	-	-	-	-	-0.26	-	-0.21	-0.22	1.95	-0.48	-	-	0.71	-	-	-0.16	-	-	-0.13	-0.17	-0.22	-0.21	-0.20	-0.17	-0.18	-0.07	0.01	-0.04	0.00	-0.07
R&D Expense	20.86M	20.77M	23.11M	-	37.00M	48.22M	52.53M	-	43.58M	26.93M	39.14M	-	47.70M	26.48M	13.76M	-	12.02M	12.64M	26.66M	-	55.18M	57.30M	40.15M	12.61M	10.26M	15.68M	14.93M	13.36M	10.56M	12.03M	14.54M	17.56M	14.37M	17.64M	25.78M	15.30M	15.75M	18.76M	12.76M	17.44M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	10.70M	4.91M	1.85M	1.09M	2.22M	22.85M	130.01M	0	15.89M	26.58M	32.33M	23.40M	-	139.00K	1.20M	31.08M	49.80M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	0	85.00K	616.00K	274.00K
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	139.00K	1.12M	30.46M	49.53M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	100.90M	172.87M	227.58M	98.44M
Operating Income	-89.96M	-95.72M	-114.09M	-108.42M	-102.37M	-100.37M	1.47M	-127.17M	-130.62M	-103.28M	141.44M	-47.80M	-	-100.76M	-171.75M	-197.12M	-48.91M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-98.74M	-163.46M	-184.29M	-41.38M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	2.78M	13.10M	15.58M	8.34M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-101.94M	-177.12M	-200.40M	-50.34M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Net Income	-82.78M	-101.78M	-116.22M	-110.21M	-104.13M	-100.29M	-4.68M	-131.44M	-122.99M	-120.55M	130.13M	-58.57M	-	-101.94M	-177.12M	-200.40M	-50.34M
Diluted EPS	-	-	-	-	-	-	-	-	-1.17	-1.14	1.16	-0.53	-	-0.62	-0.79	-0.63	-0.14
R&D Expense	81.24M	78.52M	91.83M	82.57M	89.68M	89.28M	95.19M	163.97M	152.22M	100.24M	91.92M	153.62M	55.05M	52.82M	58.89M	84.48M	61.12M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	366.88M	430.51M	371.78M	274.16M	471.38M	651.96M	475.62M	436.54M	284.14M	417.71M	203.79M	-	194.30M	229.43M	298.42M	184.99M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	140.87M	176.55M	246.19M	101.89M
Cash & Equivalents	85.87M	100.55M	47.21M	186.31M	30.42M	37.50M	137.27M	202.99M	46.60M	61.66M	80.39M	36.11M	126.26M	-	46.34M	22.46M	66.66M	34.33M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	381.00K	231.00K	281.00K
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28.00K	1.01M	3.47M	2.38M
Total Liabilities	-	-	119.86M	132.94M	105.10M	104.00M	187.36M	366.11M	318.22M	368.27M	310.54M	300.61M	47.42M	-	77.17M	136.32M	152.47M	77.45M
Current Liabilities	-	-	10.78M	21.39M	18.29M	19.29M	44.97M	122.96M	164.64M	105.49M	36.75M	65.34M	46.81M	-	23.17M	31.55M	45.25M	20.87M
Long Term Debt	-	-	27.34M	23.45M	21.88M	20.17M	87.50M	100.96M	85.17M	231.58M	243.89M	234.17M	0	-	48.58M	99.51M	100.30M	49.41M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.29M	106.06M	108.40M	62.82M
Total Equity	195.83M	163.50M	247.02M	297.57M	266.68M	170.16M	284.02M	285.97M	167.51M	68.27M	-26.41M	117.10M	156.37M	-	117.12M	93.11M	145.95M	107.54M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	189.21M	245.79M	363.02M	365.85M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-89.02M	-82.37M	-87.94M	-94.46M	-91.08M	-75.62M	184.78M	-175.63M	-185.39M	-148.61M	113.81M	-142.97M	-87.02M	-88.85M	-161.90M	-178.78M	-67.85M
Investing Cash Flow	11.88M	-113.84M	69.95M	-97.81M	99.54M	-108.42M	-117.02M	18.25M	50.52M	169.58M	-155.85M	380.76M	2.11M	-71.08M	-49.94M	-15.38M	113.02M
Financing Cash Flow	91.82M	142.87M	157.08M	36.38M	-1.39M	283.81M	-2.03M	987.00K	149.93M	-2.24M	-2.23M	-147.64M	22.71M	142.21M	187.96M	238.35M	-48.50M
Capital Expenditure	-369.00K	-1.13M	-1.21M	-492.00K	-1.72M	-80.00K	-910.00K	-231.00K	-228.00K	-95.00K	-70.00K	-87.00K	-1.22M	-1.33M	-470.00K	-1.03M	-0
Free Cash Flow	-89.39M	-83.50M	-89.14M	-94.95M	-92.80M	-75.70M	183.87M	-175.86M	-185.62M	-148.70M	113.74M	-143.06M	-88.24M	-90.18M	-162.37M	-179.81M	-67.85M
Share Buybacks	88.00K	149.00K	108.00K	285.00K	873.00K	887.00K	357.00K	621.00K	1.68M	972.00K	941.00K	1.03M	2.67M	864.00K	824.00K	1.73M	-

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	100.0%	92.9%	98.0%	99.4%
Operating Margin %	-840.7%	-1,950.2%	-6,170.6%	-9,955.5%	-4,607.2%	-439.2%	1.1%	-	-822.1%	-388.5%	437.5%	-204.2%	-	-72,489.2%	-14,265.0%	-634.2%	-98.2%
Net Margin %	-773.6%	-2,073.7%	-6,285.3%	-10,120.4%	-4,686.1%	-438.8%	-3.6%	-	-774.0%	-453.5%	402.5%	-250.3%	-	-73,341.0%	-14,710.9%	-644.8%	-101.1%
ROE %	-50.6%	-41.2%	-39.1%	-41.3%	-61.2%	-35.3%	-1.6%	-78.5%	-180.2%	456.5%	111.1%	-37.5%	-	-87.0%	-190.2%	-137.3%	-46.8%
ROCE %	-	-26.9%	-27.9%	-30.7%	-40.2%	-23.5%	0.3%	-40.9%	-39.5%	-41.7%	40.1%	-30.4%	-	-58.9%	-86.8%	-77.9%	-29.8%

Shareholding Pattern

Insiders

1.12%

Institutions

83.75%

Public Float

84.70%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Artal Group S.A.	39.36%	175.16M	$359.07M
2	FMR, LLC	11.64%	51.78M	$106.15M
3	Siren, L.L.C.	9.96%	44.30M	$90.82M
4	Sessa Capital IM, L.P.	4.26%	18.96M	$38.87M
5	Blackrock Inc.	3.90%	17.35M	$35.56M
6	Vanguard Capital Management LLC	2.23%	9.90M	$20.30M
7	Point72 Asset Management, L.P.	1.85%	8.25M	$16.92M
8	Geode Capital Management, LLC	1.40%	6.24M	$12.80M
9	State Street Corporation	1.11%	4.92M	$10.08M
10	Vanguard Portfolio Management LLC	0.53%	2.36M	$4.83M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LXRX

Google News Sat, 05 Sep 2026

Here's Why You Should Add LXRX Stock to Your Portfolio Now - Eastern Progress

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPZWlsMXNwSWJQUzF3YkZtMEpCeTNPR3JyRFpieTNpcUYwaHdaNmpqSFFYdl84OVo3VzdNaTEtSkJRdTdyYy1Oakt2TEpIanZyWGlxUkhrTGwxNmwtMk5uQ1BieDNhQ2pfR1k3TjFQcEZMTnJqX2F4dmtGdzlNdmtjcXBFQzg0RHBhWEg0Nl…

Google News Sat, 05 Sep 2026

Lexicon Pharmaceuticals Stock Price Forecast. Should You Buy LXRX? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE13Qk9iTVU2Zm1kX1d4dm11SlBsNWNnUGtFT1VjME8zaXZKcUFOWG03WnZiWWNvaFppQlR2WDFvSkhvTHNVUlhRNA?oc=5" target="_blank">Lexicon Pharmaceuticals Stock Price Forecast. Should You Buy LXRX?</a…

Google News Mon, 07 Sep 2026

How Investors Are Reacting To Lexicon (LXRX) Heart Failure Data In Low-Blood-Pressure Patients - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxORTd5S0x2aEQ4UWFWZGRXTDVyWExyWFQzZlZHTHdTbVlFQjJXd18wY3B2Q0ZuaXdFOW1LNlRfbEFKM0FUNU1hNGJRdFllYXVDaUo4MmpDazNpS3BMN2h6TllMWVJiRThnXzUwcHlMcUFlN0o5aDlMYjc5bnFaMEZWcWY1bEE0dXJJUGd1dH…

Google News hu, 11 Jun 2026

Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQRlBLNVlPOWk3bEstSU5CMFRMUGtiYU9NUkluMThVZHNJUUF4dnRIZnNZckczenpVTnhMdVFXbFJURE0zVExpZm5zTnl4WEpyWUh1WVREVUxDekdRZ2UtenFiY2tSSC1DUGozRTVqVnU5Ry1lS3pabHBJbFMxdWhON09RYUdsNHJHTDdpa3…

Google News hu, 30 Jul 2026

Lexicon schedules Aug. 6 call and webcast for Q2 results - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOS25lSzBoY2hYTkJIN2FxeEFDLWhYdTlVTEoxX1FfUXp1eE5aWnVKYUgtX3pNTkRtdXhERDkzNnBUcTI1ZEU1Q29sQ2M5ZEFQMXFyNEF0d2xwSkRtR2wyX2tjT1BMZ2VjdXFOeTNzcEV1bmdTanNqa3p5TzF1VGR5YjFCTUlGbjVRWVA5Zk…

Google News Mon, 24 Aug 2026

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon - TradingView

<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxPV1R5QUVhTzRxQmRWTGU2ZmFxNXZVSmdUb3UzR01EWldzTUVYSEJxc0tHeWxQZEpiU3BBU1NDZEpXaTBUMFFjaW02Q3VOUlVzYzNQUUwwTjFBeGcxY2k3Zy1UVGt5eHZ3QWRZbGNpLUV5X0hsaDU5cmU5MmVOcm1BcFNoNEZ5VDhLR3BRYn…

LXRX — Frequently Asked Questions

What is the current share price of Lexicon Pharmaceuticals, Inc. (LXRX)?

As of 2026-09-19 21:16 PDT, Lexicon Pharmaceuticals, Inc. (LXRX) trades at $2.23 on NasdaqCM. Its 52-week range is $1.07 to $2.64.

What is the market capitalisation of LXRX?

Lexicon Pharmaceuticals, Inc. (LXRX) has a market capitalisation of $992.25M on NasdaqCM.

What is the P/E ratio of LXRX?

LXRX trades at a trailing price-to-earnings (P/E) ratio of -13.94. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.23.

What is the return on equity (ROE) of LXRX?

LXRX has a return on equity (ROE) of -40.21%. Its return on capital employed (ROCE) is -29.80%.

Is LXRX a good stock to buy?

This page provides a data-driven analysis of Lexicon Pharmaceuticals, Inc. (LXRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Lexicon Pharmaceuticals, Inc. LXRX R3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Here's Why You Should Add LXRX Stock to Your Portfolio Now - Eastern Progress

Lexicon Pharmaceuticals Stock Price Forecast. Should You Buy LXRX? - StockInvest.us

How Investors Are Reacting To Lexicon (LXRX) Heart Failure Data In Low-Blood-Pressure Patients - simplywall.st

Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? - finance.yahoo.com

Lexicon schedules Aug. 6 call and webcast for Q2 results - Stock Titan

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon - TradingView

LXRX — Frequently Asked Questions

What is the current share price of Lexicon Pharmaceuticals, Inc. (LXRX)?

What is the market capitalisation of LXRX?

What is the P/E ratio of LXRX?

What is the return on equity (ROE) of LXRX?

Is LXRX a good stock to buy?

Explore More